DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Dado Ruvic - 1 Ashley Kirzinger - 1 Kirzinger - 1 BioNTech - 1 Jefferies - 1 Michael Yee - 1 " Yee - 1 Mandy Cohen - 1
Top related locs:
U.S America United States COVID CDC's
Top related orgs:
REUTERS - 1 CVS Health - 1 Family - 1 Pfizer – - 1 Moderna - 1 Pfizer - 1 U.S . Centers for Disease Control - 1 Prevention - 1

Search resuls for: "David Boulware"


3 mentions found


☆ New Covid vaccines are on the way as 'Eris' variant rises
  + stars: | 2023-08-14 | by ( Michael Erman | ) www.reuters.com   time to read: +5 min
Some public health experts hope that Americans will welcome the new shot as they would a flu jab. In the fall of 2022, by which time most people had either had the COVID virus or the vaccine, fewer than 50 million people got the shots. Its biggest rival, Moderna, conceded demand could be as few as 50 million shots. POST PANDEMIC VACCINEThe COVID public health emergency ended in May and the government has handed much of the duty of vaccinating America to the private sector. As with the flu, Pfizer (PFE.N)/BioNTech SE (22UAy.DE), Moderna (MRNA.O) and Novavax (NVAX.O), have created versions of the COVID vaccine to try to match the variant they believe will be circulating this fall.
Persons: Dado Ruvic, Ashley Kirzinger, Kirzinger, BioNTech, Jefferies, Michael Yee, " Yee, Mandy Cohen, William Schaffner, Schaffner, David Boulware, Michael Erman, Caroline Humer, Diane Craft Organizations: REUTERS, CVS Health, Family, Reuters, Pfizer –, Moderna, Pfizer, U.S . Centers for Disease Control, Prevention, CDC, U.S . Food, Drug Administration, EG, Vanderbilt University, University of Minnesota, Thomson Locations: U.S, America, United States, COVID, CDC's
☆ Moderna flu vaccine delivers mixed results in trial, shares fall
  + stars: | 2023-02-16 | by ( Patrick Wingrove Michael Erman | Patrick Wingrove | Michael Erman | ) www.reuters.com   time to read: +3 min
It failed to meet its goal of non-inferiority compared to the conventional vaccine for the B/Victoria and B/Yamagata-lineage strains, the drugmaker said. "We have always said our goal is to produce a flu vaccine, and then to iterate it, and to fine tune it over time to really make it exceptional," Chief Medical Officer Paul Burton said in an interview. Seventy percent of those who received Moderna's shot reported mostly mild adverse reactions compared to 48% for the conventional flu vaccine. The company also has an ongoing late-stage efficacy study on the mRNA-1010 flu vaccine, which could have data within weeks. The flu, an infection of the nose, throat and lungs, kills 290,000 to 650,000 people worldwide annually.
☆ Pfizer-BioNTech releases first human results on updated booster, citing an increase in antibodies
  + stars: | 2022-10-13 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Berkeley-Lovelace-Jr.Jpg | Berkeley Lovelace Jr. | ) www.nbcnews.com   time to read: +3 min
The results are based on blood samples taken from adults one week after they received the updated booster. The FDA also authorized Moderna's updated booster based on similarly limited data. The FDA authorized the updated shots based on studies in mice — plus human trial results from a similar booster that targets the original omicron strain, called BA.1. At the time, Dr. Peter Marks, the FDA's top vaccine regulator, said the agency hoped the updated vaccines will provide stronger protection against symptomatic disease than the older vaccines. Moderna didn't immediately respond to a request for comment about when it will release new data on its updated booster.
0 next >>
Total: 3